Thymosin Alpha 1 Restores Immune Balance in Long COVID Patients

Many individuals experience Post-Acute Sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID, characterized by persistent symptoms and significant immune dysregulation. This dysregulation often involves imbalances in lymphocyte populations, which are critical immune cells, leading to chronic inflammation and impaired immune responses. There is an urgent need for therapeutic strategies that can effectively restore immune homeostasis and alleviate the debilitating effects of Long COVID.

Treatment with Thymosin alpha 1 led to significant improvements across several immune parameters in Long COVID patients. Specifically, there was a notable increase in CD3+ T cells and CD4+ T cells, which are crucial for adaptive immunity, while markers of T cell activation, such as CD38 and HLA-DR on CD8+ T cells, were significantly reduced. This suggests a normalization of T cell function and a decrease in chronic immune activation. > The most important finding was a significant increase in the CD4+/CD8+ ratio from 0.8 ± 0.1 at baseline to 1.4 ± 0.2 after 4 weeks of treatment (p < 0.001), indicating a crucial restoration of immune balance. Furthermore, the study observed a significant decrease in the levels of pro-inflammatory cytokines IL-6 and TNF-α, suggesting a reduction in systemic inflammation. B cell and NK cell counts were also modulated towards healthier, more balanced levels.